LINC AB

Research LINC AB (6ZB) on Bullrun: market cap EUR 379.00M, P/E 12.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 379.00M; P/E is 12.8.

Peer valuation comparison

Latest P/E is 12.84x versus a Financial Services sector median of 13.84x (7.2% below).

Latest P/E is 12.84x versus a Sweden median of 18.57x (30.8% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2024n/aSEK 1.30Bn/an/an/aSEK 549.66Mn/aSEK 4.83B
FY2023n/aSEK 619.46Mn/an/a22.5SEK 519.98Mn/aSEK 3.53B
FY2022n/a-SEK 723.34Mn/an/a10.7SEK 600.55Mn/aSEK 2.91B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27EUR 379.00M12.8n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About LINC AB

Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies. The firm prefers to invest in Nordic companies.

Related stock research

Other Financial Services stocks

Frequently asked questions

What is LINC AB's market cap?

LINC AB's market capitalization is EUR 379.00M.

What is LINC AB's P/E ratio?

LINC AB's price-to-earnings (P/E) ratio is 12.8.

What does LINC AB do?

Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies. The firm prefers to invest in Nordic companies.